These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21513002)

  • 1. 'Free' prostate cancer screens can be costly.
    Consum Rep; 2011 May; 76(5):12. PubMed ID: 21513002
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 3. Death knell for PSA screening?
    Mani H
    Natl Med J India; 2011; 24(6):380. PubMed ID: 22680272
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 5. PSA screening: the USPSTF got it right.
    Lefevre M
    J Fam Pract; 2013 Nov; 62(11):617, 619. PubMed ID: 24288702
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 8. Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection.
    Ficarra V; Novara G; Galfano A
    Eur Urol; 2009 Mar; 55(3):556-9. PubMed ID: 19111385
    [No Abstract]   [Full Text] [Related]  

  • 9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helping men make decisions about PSA tests.
    BMJ; 2013 Jul; 347():f4785. PubMed ID: 23903252
    [No Abstract]   [Full Text] [Related]  

  • 11. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions.
    Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799
    [No Abstract]   [Full Text] [Related]  

  • 14. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 15. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
    Ablin RJ; Sartor O; Bennett CL
    Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 17. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
    Schostak M; Schwall GP; Poznanović S; Groebe K; Müller M; Messinger D; Miller K; Krause H; Pelzer A; Horninger W; Klocker H; Hennenlotter J; Feyerabend S; Stenzl A; Schrattenholz A
    J Urol; 2009 Jan; 181(1):343-53. PubMed ID: 19012935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numbers needed to decide.
    Woloshin S; Schwartz LM
    J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.